Heplisav’s Hopes For U.S. Approval Could Rest On Narrower Population
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a “complete response” letter for the novel, adjuvanted hepatitis B vaccine, FDA cites the need for more safety data in the broad population of adults for which approval was sought; however, Dynavax says the agency appears open to considering a more restricted use, such as in patients with chronic kidney disease.
You may also be interested in...
Dynavax Will Not Pursue Narrow Indication For Heplisav After Meeting With FDA
The company will be collecting additional safety data for approval of its hepatitis B vaccine in adults 18 to 70 years old; the size, duration and cost of the study are yet to be determined.
Vaccine Adjuvant Heightens Panel’s Worries About Rare Adverse Events With Heplisav
FDA’s Vaccines and Related Biological Products Advisory Committee recommended 8 to 5 with one abstention that Dynavax acquire more safety data pre-licensure for its hepatitis B vaccine.
FDA Panel Considers Dynavax’s Heplisav Safety Database Insufficient
The sponsor’s proposal for a post-approval cohort safety study in 30,000 patients failed to alleviate the concerns of a majority of the vaccines advisory committee, which voted 8 to 5 with one abstention that available data do not support the safety of the hepatitis B vaccine.